Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019
Paris, October 18, 2018 – 6:30 pm CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced that the Company was invited to present an overview of AsiDNA™ for the treatment of solid tumors at the 2nd DNA Damage Response Therapeutics Summit (DDRTS) to be held January 29-31, 2019, in Boston, MA.
This leading industry summit provides the opportunity to gain exclusive insights on the latest innovations in the field of tumor DNA Damage Response. The presence of prominent pharmaceutical groups and research institutions testifies to the attractiveness of this rapidly growing field.
Onxeo will present an overview of AsiDNA™, the Company’s first-in-class compound targeting tumor DNA break repair pathways, during a session entitled, “New Developments in PARP Inhibitors & Novel DDR Pathway Targets.”
Françoise Bono, Chief Scientific Officer of Onxeo, said: “AsiDNA™ has shown unique properties in translational research, notably its ability to prevent resistance to PARP inhibitors and to potentiate their activity in cancer cells, regardless of genetic mutation status. Its strong synergy with DNA-damaging agents, such as chemotherapies and PARP inhibitors, could also open new therapeutic options in difficult-to-treat cancers. We are pleased to have been selected to present at this benchmark event among the world’s most recognized stakeholders in DNA Damage Response. This is the ideal forum to update the industry, scientific and clinical experts on the recent clinical development progress achieved with AsiDNA™, a highly-differentiated molecule acting upstream of multiple DNA damage response pathways.”
Session: New Developments in PARP Inhibitors & Novel DDR Pathway Targets
Date: Wednesday, January 30, 2019
Time: 2:00 pm
Location: Revere Hotel Boston Common, 200 Stuart St., Boston, MA 02116
Onxeo’s presentation: AsiDNA™, A First-in-Class Decoy Oligonucleotide Targeting DNA Repair to Kill Tumor Cells
- AsiDNA™ is an innovative global DNA damage response inhibitor preventing recruitment of enzymes involved in DSB and SSB repair at the damage site
- AsiDNA™ is synergistic with PARP inhibitors, prevents and reverses PARPi-acquired resistance
- Recent outcomes from the phase 1 clinical study of AsiDNA™
For further information, please visit the DNA Damage Response Therapeutics Summit website